Protherics reports Digibind data

Protherics (LSE:PTI; NASDAQ:PTIL) said Digibind met one of the two primary endpoints in the Phase IIb DEEP trial in 51 pregnant women with severe preeclampsia for whom baby delivery was necessary with...